Christopher James Frankenfield - 03 Aug 2023 Form 3 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
Chief Operating Officer
Signature
/s/ Julia Walcott, Attorney-in-Fact
Issuer symbol
XLO
Transactions as of
03 Aug 2023
Net transactions value
$0
Form type
3
Filing time
07 Aug 2023, 16:09:49 UTC
Next filing
18 Aug 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding XLO Stock Option (right to buy) 03 Aug 2023 Common Stock 155,090 $6.65 Direct F1
holding XLO Stock Option (right to buy) 03 Aug 2023 Common Stock 23,786 $6.65 Direct F2
holding XLO Stock Option (right to buy) 03 Aug 2023 Common Stock 37,296 $16.00 Direct F3
holding XLO Stock Option (right to buy) 03 Aug 2023 Common Stock 45,000 $12.66 Direct F4
holding XLO Stock Option (right to buy) 03 Aug 2023 Common Stock 20,000 $2.13 Direct F5
holding XLO Stock Option (right to buy) 03 Aug 2023 Common Stock 117,000 $2.69 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on March 29, 2021 for 155,090 shares. On March 27, 2022, 25% of the shares of common stock underlying the stock option vested and the remainder continues to vest in equal monthly installments thereafter through March 27, 2025.
F2 The option was granted on April 1, 2021 for 23,786 shares. On March 27, 2022, 25% of the shares of common stock underlying the stock option vested and the remainder continues to vest in equal monthly installments thereafter through March 27, 2025.
F3 The option was granted on October 21, 2021 for 37,296 shares. The shares underlying the option began vesting on November 1, 2021 and shall vest in equal monthly installments thereafter through October 1, 2025.
F4 The option was granted on February 22, 2022 for 45,000 shares. The shares underlying the option began vesting on March 1, 2022 and shall vest in equal monthly installments thereafter through February 1, 2026.
F5 The option was granted on September 1, 2022 for 20,000 shares. The shares underlying the option began vesting on September 1, 2022 and shall vest in equal monthly installments thereafter through August 1, 2026.
F6 The option was granted on January 1, 2023 for 117,000 shares. The shares underlying the option began vesting on February 1, 2023 and shall vest in equal monthly installments thereafter through January 1, 2027.

Remarks:

Exhibit Index: 24.1 Power of Attorney